Key result
African-American individuals had significantly lower circulating NT-proBNP levels compared with other racial/ethnic groups at baseline and after two years of preventive interventions.
Why the study?
Few studies have examined whether circulating natriuretic peptide levels and their response to preventive interventions for DM2 differ by race or ethnicity.
Do circulating NT-proBNP levels and their response to preventive interventions for type 2 diabetes differ by race/ethnicity?
Observational (n=3,220)
Yes
Do circulating NT-proBNP levels and their response to preventive interventions for type 2 diabetes differ by race/ethnicity?
African-American individuals have significantly lower circulating NT-proBNP levels compared to other racial/ethnic groups at baseline and after two years of preventive interventions for type 2 diabetes, suggesting a relative natriuretic peptide deficiency.
Answers are grounded in this paper and cite their sources.
May warrant race-specific NT-proBNP thresholds in diabetes prevention; leaves open effects on outcomes and tailored interventions.
Natriuretic peptides are cardiac-derived hormones that enhance insulin sensitivity and reduce fat accumulation. Low natriuretic peptide levels are associated with increased risk of type 2 diabetes mellitus (DM2); a condition with variable prevalence across racial/ethnic groups. Few studies have examined whether circulating natriuretic peptide levels and their response to preventive interventions for DM2 differ by race/ethnicity. The Diabetes Prevention Program (DPP) is a clinical trial (July 31, 1996- July 31, 2001) that randomized participants to preventive interventions for DM2. Using stored serum samples, we examined N-terminus pro-B-type natriuretic peptide (NT-proBNP) levels in 3,220 individuals (56% white; 19% African-American; 15% Hispanic; 5% American-Indian; 5% Asian). The influence of race/ethnicity on NT-proBNP concentrations at baseline and after two years of treatment with placebo, lifestyle, or metformin was examined with multivariable-adjusted regression. At baseline, NT-proBNP differed significantly by race (P < .001), with the lowest values in African-American individuals. Hispanic individuals also had lower baseline NT-proBNP levels compared with whites (P< .001), while NT-proBNP levels were similar between white, American-Indian, and Asian individuals. At two years of follow-up, NT-proBNP levels decreased in African-Americans in each of the DPP study arms, whereas they were stable or increased in the other racial/ethnic groups. In the DPP, African-American individuals had lower circulating NT-proBNP levels compared with individuals in other racial/ethnic groups at baseline and after two years of preventive interventions. Further studies should examine the cardio-metabolic implications of lower natriuretic peptide levels in African-Americans. Trial Registration: ClinicalTrials.gov NCT00004992.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2020) conducted an observational in Impaired glucose tolerance (n=3,220). African-American race vs. White race was evaluated on Baseline NT-proBNP levels (ng/L) (p=<0.001). African-American individuals had significantly lower circulating NT-proBNP levels compared with other racial/ethnic groups at baseline and after two years of preventive interventions.
Synapse has enriched 10 related papers. Consider them for comparative context: